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SUMMARY AND DISCUSSION 
Despite important progress in perinatal medicine, respiratory distress syndrome (RDS) 
remains one of the most important causes of mortality and morbidity, especially in prem-
ature infants. The classic entity of neonatal respiratory distress syndrome, as a lung dis-
ease expressing predominant surfactant deficiency, is currently changing to a more com-
plex disease of the extremely immature and the developing lung [1].  
Although mortality and morbidity rates have decreased in term and preterm infants 
over the past three decades with the advent of antenatal steroids, the introduction of 
surfactant replacement therapy, and some advances in mechanical ventilation, long-term 
morbidity and the new BPD have not [1-3]. Despite using sophisticated ventilators and 
ventilation modes and advances in understanding mechanical ventilation, it is becoming 
evident that improvement in outcomes cannot be fully achieved by restoring normal lung 
physiology [4,5]. In this regard, a more specific, physiological, gentle and tailored ventila-
tion strategy should be based on: i) careful data recording of perinatal history and treat-
ments (i.e. steroids prophylaxis), ii) optimization of the delivery room and transitional 
phase management allowing to recruit and keep the lung open (i.e. SLI), iii) maintenance 
of FRC, supporting the spontaneous respiratory drive thus reducing apnea episodes and 
improving gas exchange, iv) decreasing the work of breathing, and v) limiting the VILI [6-
9]. Altogether, it is essential to strike a balance between oxygenation, CO2 removal and 
the implications of higher than normal airway pressures, since optimizing one might come 
at the expense of the other. In addition to the ventilation strategies, the general treat-
ment goals are: a) to protect the central nervous system; b) to guarantee haemodynamic 
equilibrium and appropriate PDA management; c) to give adequate nutritional intake and 
improve feed tolerance; d) to avoid infection. 
VILI remains a major issue in neonatal intensive care. In this perspective, in the last 
few decades there has been widespread diffusion of N-CPAP, as a non-invasive respira-
tory support and as a primary approach in the management of RDS in preterm infants, 
due to its capacity to reduce the occurrence of BPD; however, N-CPAP failure rates still 
remain high (30-50%) in preterm infants [10-13]. 
For these reasons, in recent years, the efforts of scientific and technological research 
have focused on trying to identify which NIV strategy was the most effective to avoid the 
use of MV or, whenever this was inevitable, what the best invasive or non-invasive venti-
lation technique could be to limit the time of MV and/or endotracheal intubation, in order 
to avoid VILI and BPD [14-15].  
New ventilation techniques have been developed since 1980, such as HFOV, using 
tidal volumes smaller than anatomical dead space delivered at a very high rate of 600 to 
900 bpm. The aim was to avoid the large volume swings seen with CMV thereby offering 
the potential for lung protective ventilation. Since volutrauma, atelectotrauma and to a 
lesser extent barotrauma are seen as main determinants in the development of VILI, 
HFOV could be considered as a lung protective mode of ventilation [16-18]. 
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Moreover, since 1990 there has been considerable progress in the development of 
new devices and interfaces for NIV in preterm babies, that have made different tech-
niques of NIV available and that could be more effective than N-CPAP, thus avoiding MV 
[19-20]. Indeed, the introduction of newer NIV methods has allowed to reduce the times 
of MV but it is still unclear whether they are really effective in reducing the BPD, also 
because these NIV techniques are quite heterogeneous and further large RCT are needed 
[21-23]. 
In this regard, the aims of this thesis were to compare the effectiveness of various 
techniques of ventilation respiratory support, both invasive and non-invasive, in order to 
reduce the need of CMV.  
In Chapter 2, we investigated the effectiveness of two invasive respiratory strategies as 
first intention treatment, HFOV and CMV, in a randomized cohort of PN in whom antena-
tal steroids prophylaxis was not performed. We enrolled 88 VLBW infants, <30 wGA, who 
needed ventilation support (HFOV: n=44; CMV: n=44) within 2-h from birth, in three NI-
CUs in which HFOV was usually used and with neonatologists staff who are highly experi-
enced with both ventilation methods. We showed that HFOV, in a selected population of 
high risk newborns in which glucocorticoid prophylaxis was not performed, was more ef-
fective than CMV in terms of: shorter duration of ventilation, successful extubation, 
shorter duration of N-CPAP support after MV, and of hospitalization. Mortality, BPD and 
other secondary outcomes rates (PNX, NEC, ROP, IVH, etc.) did not differ between the 
two groups.  
These promising results could be due to an early application of HFOV, as first intention 
ventilation treatment for RDS, associated with an open lung strategy [18,24-25]. This al-
lowed recruiting the collapsed alveoli to achieve an adequate FRC and to stabilize the 
lung [18,26]. Furthermore, the maintenance of the newborn’s spontaneous respiratory 
drive, with inspiration and expiration during the oscillation on a constant level of pressure 
(continuous distending pressure), could favor the weaning from invasive ventilation to N-
CPAP [16]. Despite the limitation due to the small sample size, the population of the study 
was homogeneous and bias was avoided by an early randomization (within 2-h from 
birth) and by excluding crossover between the two groups. Taking into account the high 
risk for RDS in the absence of GC-treatment, the potential bias of surfactant administra-
tion was avoided by administrating prophylactic surfactant to all infants admitted into the 
study. 
All these aspects and more (e.g. delivery room management, SLI, early N-CPAP, sur-
factant, PDA management, etc.) could play an important role in the effectiveness of the 
ventilation strategy with a possible benefit on the reduction of VILI and BPD; however, 
well-designed and large trials are needed to define this [9].  
Several trials to compare HFOV and CMV have been conducted in the last few years. 
The recent Cochrane meta-analysis of Cools et al. concluded that the use of elective HFOV 
compared with CMV results in a small reduction in the risk of BPD. However, the evidence 
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is weakened by the inconsistency of this effect across trials, even after the meta-analysis 
was restricted to studies that applied a high lung volume strategy with HFOV [24]. Prob-
ably many factors, related both to the intervention itself as well as to the individual pa-
tient, interact in complex ways. In particular, clinical trials in which HFOV was compared 
to CMV are extremely heterogeneous in terms of: strategy of ventilation (HFOV first in-
tention or rescue), open lung strategy performed or not, guaranteed volume applied in 
CMV, setting parameters, surfactant treatment, time of randomization, cross-over be-
tween the two groups, FiO2 and PaCO2 tolerated, gestational age and birth-weight of the 
newborn [16,24]. In addition, the benefits could be counteracted by an increased risk of 
acute air leak.  
A limitation of the present study was that, in the CMV group we did not perform an 
open lung strategy and/or a more protective ventilation method with volume guaran-
teed. The explanation resides in the fact that open lung strategy in the CMV group was 
not considered standard of care at that time.  
Finally, the present observation offered further support to the debated issue on the 
best first intention invasive ventilation strategy for RDS treatment. Further multicenter 
RCTs in a larger population are therefore needed also to investigate HFOV effects on long-
term outcomes. 
Although invasive ventilation remains the only viable alternative and life-saving treat-
ment for critically ill babies, neonatologists focus on what could be the best NIV strategy 
for RDS treatment. To date, N-CPAP is the most widely used method although not always 
effective [6,10,14]. Therefore, the aim of the research was to find alternative NIV tech-
niques to enhance success and to decrease CMV rates [23,27,28]. Recently, two different 
methods of nasal ventilation support have been proposed: i) N-SIPPV, which is a modality 
of conventional ventilation, with intermittent peak inspiratory pressure delivered by a 
conventional ventilator, equipped with a nasal flow sensor to allow synchronization, and 
ii) BiPAP a non-synchronized modality, that provides two different levels of N-CPAP (lower 
and higher CPAP), whereby the infant can breathe spontaneously, delivered by a flow 
driver device associated with a nasal CPAP generator (CPAP variable flow, Coanda’s ef-
fect) [28,31]. 
Therefore, in Chapters 3 and 4 we evaluated the efficacy of these two NIV strategies (N-
SIPPV and BiPAP) for RDS treatment in VLBW infants. First, we conducted a retrospective 
study in 78 preterm newborns (N-SIPPV: n=33; BiPAP: n=45), and secondly a RCT bi-cen-
ter trial enrolling 124 VLBW infants (N-SIPPV: n=62; BiPAP: n=62). Primary outcomes were 
the duration of ventilator support and NIV failure. In the RCT, the infants who had signs 
of respiratory failure at birth were treated with SLI and N-CPAP in addition to the Ameri-
can Academy of Pediatrics (AAP) recommendations [32]. The newborns included in the 
studies were not intubated and started on NIV support within 2-h from birth. Both studies 
showed similar results: the number of failures and duration of NIV support did not differ 
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between the two strategies and were not GA-dependent. Moreover, no differences be-
tween groups were found regarding secondary outcomes (PNX, NEC, IVH, BPD, etc.). Of 
note, a high rate of EOS as a cause of failure in both groups was observed.  
In our RCT, we found a low failure rate (18 out of 124 newborns, 15%) and a short 
median duration of respiratory support (N-SIPPV: 89-h; BiPAP: 87-h). These data could be 
explained as the results of a more comprehensive strategy of RDS treatment starting with 
prenatal glucocorticoid prophylaxis (85-90% for our population), delivery room manage-
ment (SLI, early N-CPAP and early surfactant replacement by INSURE), first intention NIV 
support, physician’s experience with NIV techniques and last but not least the nursing 
care [9,20,32-34].  
These are the first studies that compare two different NIV techniques with similar 
results and theoretical benefits. The theoretical advantages are: i) N-SIPPV through inter-
mittent increase in pressure enhances tidal volume (Vt), minute ventilation (Vm), and 
MAP, resulting in better alveolar recruitment and gas exchange and decreasing the work 
of breathing (WOB) [29,35], ii) BiPAP, using a much longer time of CPAPhigh (0.8-1.5 sec) 
permits a complete respiratory cycle (inspiration and expiration) on the higher CPAP level 
(expiration way is always open), creating two different FRCs. BiPAP increases MAP, and 
FRC switching generates a Vt with a better gas exchange and reduces WOB [14,19,36]. 
Additional common NIV advantages, due to pressure changes, consist in the stimulation 
of spontaneous breathing that reduces failure risk due to apneas [37].  
The present studies have some limitations such as the small sample size, which does 
not allow to show whether one technique was better than the other for BPD and mortal-
ity. Millar et al. compared two different NIV strategies (N-IPPV with conventional ventila-
tor vs BiLevel-NIPPV with a flow driver, in which the peak pressure was much lower than 
the first group) by RCT, and did not observe any difference in the composite outcome of 
death or BPD [31]. Indeed, Millar and Kirpalani highlighted the uncertainty regarding the 
effects of N-IPPV devices: these may reflect the type of device and settings used, differ-
ences in the population and other inter-unit differences that are difficult to pinpoint [31].  
Unfortunately, the abovementioned study does not clarify doubts about the superi-
ority of the theoretical advantages of synchronized methods (N-SIPPV) as against the not-
synchronized (BiPAP). Despite the known benefits of invasive triggered ventilation, one 
of the most important open questions is the efficacy of synchronization systems for nasal 
ventilation in preterm newborns. This holds for babies’ characteristics and in part the 
technical limitations of the common trigger systems used for NIV (i.e. Graseby’s capsule 
or flow sensor). In neonates, especially immature infants, it is very difficult to detect the 
inspiration phase as their spontaneous breathing is shallow and variable, thus breathing 
signals are weak or are superimposed upon a leakage flow. In our studies, for the N-SIPPV 
we used a device equipped with a specific nasal flow sensor (Giulia by Ginevri), that 
showed better tidal volume and minute volume compared with N-CPAP, in other studies, 
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and, after INSURE technique, reduction of the need of MV; however, we found no differ-
ence in effectiveness between nasal-flow synchronized-IPPV and non-synchronized (Bi-
PAP) strategies. 
We concluded that both N-SIPPV and BiPAP strategies are equally effective in the early 
treatment of RDS in VLBW infants and suggested the need of further RCTs on larger pop-
ulations to evaluate the effects of different NIV techniques on long-term outcomes.  
Although these observations showed that N-SIPPV and BiPAP were equally effective, 
no answer was provided to the question of whether they were better than N-CPAP as 
primary treatment of RDS. Several authors in smaller study populations (N-IPPV or BiPAP 
versus N-CPAP as control) and a meta-analysis reported: a) less need of MV, b) less risk 
of intubation in the first 72-h from birth, c) reduction of hospitalization duration and O2 
dependency, and d) a promising decrease in BPD [15,21,22]. Conversely, Kirpalani et al., 
in a RCT, showed no difference for BPD and death at 28 days between N-CPAP and NIV 
strategies. Discrepancies may be explained by the inclusion in the N-IPPV group of differ-
ent devices (ventilator driven or flow driver devices, synchronized or not synchronized, 
and BiLevel-CPAP) with different setting parameters [23]. 
In conclusion, at this stage, there are no studies comparing the aforementioned NIV tech-
niques with the most widely used N-CPAP [27,28]. Therefore, in Chapter 5, we conducted 
a multicenter retrospective study in order to investigate the effectiveness of the three 
different NIV methods as first intention treatment for RDS. We recruited 191 VLBW in-
fants (N-CPAP: n=66; N-SIPPV: n=62, BiPAP: n=63). For N-CPAP, we used a variable flow 
system and for the other techniques the same equipment as in the previous studies. New-
borns were supported in the DR and were admitted to the NICU on N-CPAP support and 
started on NIV support within 6-h from birth. The primary outcome was the failure rate 
within the first 5 days of life.  
We showed that N-SIPPV/BiPAP, as first intention augmented the beneficial effects of 
N-CPAP contributing to a significant reduced risk of failure in VLBW infants (N-CPAP: 
22/66; N-SIPPV; 11/62; BiPAP 11/63). Moreover, no differences were found between the 
three groups regarding the secondary outcomes (PNX, NEC, IVH, BPD, etc.). 
Of note, when we corrected the NIV failure rate for GA we found a significantly higher 
rate in the N-CPAP group, at 26-29 wGA, whilst no differences were observed in infants 
delivered at <26 wGA or >29 wGA. The absence of any differences in failure rate among 
the three NIV supports at <26 wGA may be due to: a) the severe lung immaturity and RDS 
itself, and b) to the reduced respiratory drive with very poor energy reserves to cope the 
high WOB to maintain FRC and adequate gas exchanges. Conversely, at 26-29 wGA, at a 
stage of increased lung maturity, N-SIPPV/BiPAP, with a different strategy, amplify the 
respiratory drive of the newborn and the effect of N-CPAP, thus obtaining: a) better lung 
recruitment with an adequate FRC, thanks to the higher MAP, b) better gas exchanges 
due to an increase of Vt and Vm, c) a reduction of WOB, and d) decreased risk of apneas. 
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Data on failure rate at > 29 wGA can reasonably be due to non-respiratory causes such 
as EOS, PDA, PPHN, etc.  
Finally, the absence of any difference between N-SIPPV (synchronized) and BiPAP (not 
synchronized) confirms previous observations and offers additional matter of debate 
about the real benefits and effectiveness of synchronized nasal ventilation [14,28,31,38].  
Our observation has several limitations. The main reside in: a) the study design since 
we conducted a retrospective not randomized investigation, although protocols were 
similar and standardized in all NICUs; b) the small sample size, and c) the choice made by 
the treating physician to use one or another NIV support due to device availability in 
NICU. Thus, we cannot exclude different attitudes of the neonatologists to use a specific 
NIV modality instead of the other. 
However, our data show that N-SIPPV/BiPAP augment the beneficial effects of N-CPAP 
and contribute to a reduced risk of failure in VLBW infants complicated by RDS [21,22]. 
The use of N-SIPPV/BiPAP as first intention in ELBW/VLBW infants complicated by RDS is 
therefore suggested or when N-CPAP fails. Further multicenter RCTs in a larger popula-
tion will be focused to address the following items: a) the most efficient method of NIV; 
b) the possible advantages of association with a lung recruitment strategy in DR (SLI); c) 
the real benefits of the less invasive method or of the strategy for surfactant administra-
tion; d) what would the real advantages of synchronization during NIV be, and e) what 
would the effect of NIV be on the reduction of VILI and/or BPD [15,39-43].  
  
